View Item 

Show simple item record

HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications
dc.contributor.authorKaul, Daniel R.en_US
dc.contributor.authorCinti, Sandro K.en_US
dc.contributor.authorCarver, Peggy L.en_US
dc.contributor.authorKazanjian, Powel H.en_US
dc.date.accessioned2012-03-16T15:53:41Z
dc.date.available2012-03-16T15:53:41Z
dc.date.issued1999-03en_US
dc.identifier.citationKaul, Daniel R.; Cinti, Sandro K.; Carver, Peggy L.; Kazanjian, Powel H. (1999). "HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19(3). <http://hdl.handle.net/2027.42/90068>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90068
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleHIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complicationsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDivision of Infectious Diseases, Department of Internal Medicine, Ann Arbor, Michiganen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90068/1/phco.19.4.281.30937.pdf
dc.identifier.doi10.1592/phco.19.4.281.30937en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceSkinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995; 28: 115 – 25.en_US
dc.identifier.citedreferenceOpravil M.. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gel capsule (SQV‐SGC) and nelfinavir in HIV infected individuals [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceKravcik S., Farnsworth A., Patick A., et al. Long term follow‐up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceBuss N.. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceHsu A., Granneman GR, Japour A., Cao G., Locke C.. Ritonavir and indinavir potential BID regimens [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 28October 1, 1997.en_US
dc.identifier.citedreferenceMerry C., Darry MG, Mulcahy F., Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceGallicano K., Sahai J., Kravcik S., Seguin I., Bristow N., Cameron DW. Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV‐HGC) in HIV positive patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceGisolf E., Colebunders R., Van Wanzeele F., et al. Treatment ritonavir/saquinavir versus ritonavir/saquinavir/stavudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceLorenzi P., Yerly S., Abderrakim K., et al. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997; 11: F95 – 9.en_US
dc.identifier.citedreferenceRhone S., Hogg RS, Yip B., et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV‐infected adults: results from a community‐based study. AIDS 1998; 12: 619 – 24.en_US
dc.identifier.citedreferenceGallant JE, Barnett S., Raines C., Hall C.. Efficacy and durability of ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 29July 3, 1988.en_US
dc.identifier.citedreferenceFarthing C., Mess T., Reid C., Radhakrishna S., Wallace M.. Ritonavir, saquinavir, and nevirapine as a salvage regimen for indinavir or ritonavir resistance [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceRuane PJ, Tam JT, Libraty DH, Sokolov RT, Uman SJ, Zakowski PC. Salvage therapy using ritonavir/saquinavir with a non‐nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceLallemand F., Adda N., Schneider V., Wirbel B., Jacomet C., Rozenbaum W.. Prospective follow‐up of 67 indinavir experienced HIV/AIDS patients treated with ritonavir/saquinavir combination [abstr]. In: Abstracts of the 38th international conference on antimicrobial agents and chemotherapy, San Diego, CA, September 2327, 1998.en_US
dc.identifier.citedreferenceCohen C., Siemon‐Hryczk P., Pilson R., et al. Potent and convenient Fortovase (SQV) SGC BID regimens in combination with 2 nucleosides or nelfinavir (NFV) plus 1 nucleoside in HIV‐1 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceLohmeyer J., Selhorst J., Friese G., Teichmann J., Discher T.. Combined nelfinavir/saquinavir protease inhibitor treatment in a BID regimen as salvage therapy in advanced HIV disease [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceDeeks S.. Twenty‐week HIV RNA response and correlation with baseline phenotypic drug susceptibility during treatment with a novel quadruple salvage regimen after failure of indinavir combination therapy [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceHavlir DV, Riddler S., Squires K., et al. Co‐administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetics and anti‐viral activity results [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceGallant JE, Heath‐Chiozzi M., Raines C., et al. Safety and efficacy of nelfinavir‐ritonavir combination therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceWorkman C., Musson R., Dyer W., Sullivan J.. Novel double protease combinations combining indinavir (IDV) with ritonavir (RTV): results from first study [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceHammer SM, Squires KE, Hughes ME, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725 – 33.en_US
dc.identifier.citedreferenceCameron DW, Heath‐Chiozzi M., Danner S., et al. Randomized placebo‐controlled trial of ritonavir in advanced HIV‐1 disease. Lancet 1998; 351: 543 – 9.en_US
dc.identifier.citedreferenceGulick R., Mellors J., Havlir D., et al. Treatment with indinavir, AZT and 3TC in adults with HIV and prior antiretroviral therapy. N Engl J Med 1997; 337: 734 – 9.en_US
dc.identifier.citedreferenceCarpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society. JAMA 280; 1998: 78 – 86.en_US
dc.identifier.citedreferenceAnonymous. Report of the NIH panel on principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV‐infected adults and adolescents. MMWR 1998; 47: RR‐5.en_US
dc.identifier.citedreferenceKohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1998; 85 ( 13 ): 4686 – 90.en_US
dc.identifier.citedreferenceMarkowitz M., Conant M., Hurley A., et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV‐1) protease, to treat HIV infection. J Infect Dis 1998; 177: 1533 – 40.en_US
dc.identifier.citedreferenceHammer S., Katzenstein D., Hughes M., et al. A trial comparing nucleoside monotherapy with combination therapy in HIV‐infected adults with CD4 cell counts from 200 to 500/cu cc. N Engl J Med 1996; 335: 1081 – 90.en_US
dc.identifier.citedreferenceKazanjian P., Armstrong W., Cinti S., Kaul D.. Ambulatory care of the HIV‐infected patient. Ann Arbor: Department of Medical Education, University of Michigan, 1997: 3 – 109.en_US
dc.identifier.citedreferenceMellors JW, Rinaldo CR Jr, Gupta P., White RM, Todd JA, Kingsley LA. Prognosis in HIV‐1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167 – 70.en_US
dc.identifier.citedreferencePalella FJ Jr, Delaney K., Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853 – 61.en_US
dc.identifier.citedreferenceRoche Pharmaceuticals. Fortovase (saquinavir soft gel caps) package insert. Nutley, NJ; 1997.en_US
dc.identifier.citedreferenceSlater L.. Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naïve patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15 1998.en_US
dc.identifier.citedreferenceBorleffs JC. First comparative study of saquinavir soft gel capsules vs. indinavir as part of triple therapy regimen (CHEESE) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceSension M., Farthing C., Pattison TP, Pilson R., Siemon‐Hryczyk P.. Fortovase (saquinavir soft gel capsule; SQV‐SGC) in combination with AZT and 3TC in antiretroviral‐naïve HIV‐1 infected patients [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceSchooley R.. Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV‐infected patients with 150 to 400 CD4 cells/mm3 [abstr]. In: abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, September 1518, 1996.en_US
dc.identifier.citedreferenceBart PA, Rizzardi GP, Gallan S., et al. Combination 1592/141W94 therapy in HIV‐1‐infected antiretroviral naïve subjects with CD4+ counts >400 cells/μl and viral load > 5000 copies/ml [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceHaubrich R.. Phase 2 study of amprenavir, a novel protease inhibitor, in combination with zidovudine/3TC [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceEron J., Haubrich R., Richman D., et al. Preliminary assessment of 141W94 in combination with other protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceGlaxo Wellcome. Compound 141W94 general information. Research Triangle Park, NC; 1998.en_US
dc.identifier.citedreferenceNguyen BY, Haas DW, Ramirez‐Ronda C., et al. Thirty two week follow up of indinavir sulfate administered Q8 hours versus Q12 hours in combination with zidovudine and lamivudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceProject Inform. Indinavir (Crixivan) alert! [press release] September 18, 1998.en_US
dc.identifier.citedreferenceMerck and Co. Crixivan (indinavir) drug information. West Point, PA; 1997.en_US
dc.identifier.citedreferenceLorenzi P., Yerly S., Abderrakim K., et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997; 11: F95 – 9.en_US
dc.identifier.citedreferenceAgouron Pharmaceuticals. Viracept (nelfinavir) prescribing information. La Jolla, CA; 1997.en_US
dc.identifier.citedreferenceSension M., Elion R., Farthing C., et al. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept (nelfinavir mesylate) combined with NRTIs in HIV‐infected treatment‐naïve patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceJohnson M., Petersen A., Winslade J., Clendeninn N.. Comparison of bid and tid dosing of Viracept (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceCohen C., Siemon‐Hryczyk P., Pilson R., et al. Potent and convenient Fortovase BID regimens in combination with two nucleosides or nelfinavir plus one nucleoside in HIV‐1 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 29July 3, 1988.en_US
dc.identifier.citedreferenceAbbott Laboratories. Norvir (ritonavir) drug information. North Chicago, IL; 1997.en_US
dc.identifier.citedreferenceLumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. Rockville, MD: FDA Public Health Advisory, June 11, 1997.en_US
dc.identifier.citedreferenceDong BJ, Gruta C., Legg J., Balano RH, Goldschimdt RH. Diabetes and use of protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceDubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor associated hyperglycemia. Lancet 1997; 350: 713 – 14.en_US
dc.identifier.citedreferenceKeruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceCarr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51 – 8.en_US
dc.identifier.citedreferenceMulligan K., Tai VW, Algren H., et al. Evidence of unique metabolic effects of protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceWalli RK, Herfort O., Michl GM, et al. Peripheral insulin resistance leading to impaired glucose tolerance in HIV‐1 infected patients treated with protease inhibitors. In: Conference record of the 12th World AIDS Conference, Geneva, June 28 July 3, 1998.en_US
dc.identifier.citedreferenceRoth VR, Angel JB, Kravcik S.. Development of a cervical fat pad following treatment with HIV‐1 protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceHengel RL, Geary JAM, Vuchetich MA, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceLo JC, Mulligan K., Tai V., Algren H., Schambelan M.. “Buffalo hump” in men with HIV‐1 infection. Lancet 1998; 351: 867 – 70.en_US
dc.identifier.citedreferenceViraben R., Aquilina C.. Indinavir‐associated lipodystrophy. AIDS 1998; 12: F37 – 9.en_US
dc.identifier.citedreferenceMiller KD, Jones E., Yanovski JA, Shankar R., Feuerstein I., Falloon J.. Visceral abdominal‐fat accumulation associated with the use of indinavir. Lancet 1998; 351: 871 – 5.en_US
dc.identifier.citedreferenceDong K., Flynn MM, Dickinson BP, et al. Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceCameron DW, Japour A., Mellors C., et al. Antiretroviral safety and durability of ritonavir‐saquinavir in protease inhibitor naive patients in year two of follow‐up (abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceHenry K., Melroe H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.en_US
dc.identifier.citedreferenceRoberts AD, Muesing RA, Parenti DM, Hsia J., Wasserman AG, Simon GL. Alterations in serum lipids and lipoproteins with indinavir in HIV‐infected patients. Presented at the 35th annual meeting of the Infectious Disease Society of America, San Francisco, September 1316, 1997.en_US
dc.identifier.citedreferenceBernascone E., Carota A., Magenta L., Pons M., Russotti M., Moccetti T.. Metabolic changes in HIV‐infected patients treated with protease inhibitors [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceHenry K.. Lipid abnormalities associated with use of protease inhibitors: prevalence, clinical sequelae, and treatment [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28–July 3.en_US
dc.identifier.citedreferenceKopp JB, Miller KD, Mican AM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119 – 25.en_US
dc.identifier.citedreferenceTashima KT, Horowitz JD, Rosen S.. Indinavir nephropathy [letter]. N Engl J Med 1997; 336: 138 – 9.en_US
dc.identifier.citedreferenceGinsburg C., Salmon‐Ceron D., Vassilief D., et al. Unusual occurrence of spontaneous hematomas in three asymptomatic HIV‐infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 1997; 11: 388 – 9.en_US
dc.identifier.citedreferenceHelal A.. HIV protease inhibitors and increased bleeding in hemophilia? Can Med Assoc J 1997; 156 ( 1 ): 90.en_US
dc.identifier.citedreferenceFeigal DW. FDA letter to health care providers: HIV protease inhibitors and hemophiliac patients. July 16, 1996.en_US
dc.identifier.citedreferenceYee TT, Amrolia PJ, Lee CA, et al. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997; 3 ( 3 ): 220 – 1.en_US
dc.identifier.citedreferenceRuiz I., Altisent C., Ocana I., et al. Indinavir in therapy‐experienced HIV haemophiliac patients [abstr]. Presented at the 6th European conference on clinical aspects and treatment of HIV infection, Hamburg, Germany, October 1115, 1997.en_US
dc.identifier.citedreferenceKilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug‐associated diabetes mellitus. J Acquir Hum Immune Defic Syndr Hum Retrovir 1998; 17: 46 – 50.en_US
dc.identifier.citedreferenceBristol‐Myers Squibb. Glucophage (metformin) package insert. Princeton, NJ; 1996.en_US
dc.identifier.citedreferenceBayer Corporation. Precose (acarbose) package insert. West Haven, CT; 1996.en_US
dc.identifier.citedreferenceWarner‐Lambert. Rezulin (troglitazone) package insert. Morris Plains, NJ; 1997.en_US
dc.identifier.citedreferenceGrunfeld C., Kottler DP, Hamadeh R., Tierney A., Wang J., Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27 – 31.en_US
dc.identifier.citedreferenceRovira E., Belda A., Martinez MD, Gonzalvo F., Pascual JM. The prognostic value of plasma triglycerides in HIV infections. Ann Med Interne (Paris) 1996; 147 ( 5 ): 333 – 43.en_US
dc.identifier.citedreferenceGonzalez‐Clemente JM, Miro JM, Navarro MP, Zamora L., Vilardell E.. High triglyceride levels as a predictor of mortality in AIDS patients. AIDS 1993; 7: 1022 – 3.en_US
dc.identifier.citedreferenceGrunfeld C., Feingold KR. The role of the cytokines interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992; 122: 749 – 53.en_US
dc.identifier.citedreferenceFeingold KR, Krauss RM, Pang M., Doerrler W., Jensen P., Grunfeld C.. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass B. J Clin Endocrinol Metab 1993; 76: 1423 – 7.en_US
dc.identifier.citedreferenceFeingold KR, Grunfeld C.. Tumor necrosis factor‐alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987; 80: 184 – 90.en_US
dc.identifier.citedreferenceFeingold KR, Soued M., Serio MK, Moser AH, Dinarello CA, Grunfeld C.. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989; 125: 267 – 74.en_US
dc.identifier.citedreferenceFrick MH, Elo O., Haapa K., et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987; 317: 1237 – 45.en_US
dc.identifier.citedreferenceWarner‐Lambert. Lopid (gemfibrozil) package insert. Morris Plains, NJ; 1996.en_US
dc.identifier.citedreferenceHilleman DE, Seyedroubari A.. Atorvastatin: a potent new HMG‐CoA reductase inhibitor. Cardiovasc Rev Rep 1998; 19 ( 5 ): 32 – 48.en_US
dc.identifier.citedreferenceWarner‐Lambert. Lipitor (atorvastatin) package insert. Morris Plains, NJ; 1996.en_US
dc.identifier.citedreferenceYang B‐B, Smithers JA, Siedlik PH, et al. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol [abstr]. Pharm Res 1996; 13 ( 9 suppl ): S347.en_US
dc.identifier.citedreferenceSimpson DM, Citak KA, Godfrey E., Godbold J., Wolfe DE. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 1993; 43: 971 – 6.en_US
dc.identifier.citedreferenceNational Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994; 90: 1329 – 1445.en_US
dc.identifier.citedreferenceDuncombe C., Bloch M., Austin D., Quan D.. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceCarr A., Samaras K., Chisholm DJ, Cooper DA. Pathogenesis of HIV‐1‐protease inhibitor‐associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881 – 3.en_US
dc.identifier.citedreferenceTorres R.. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceMontaner JS, Reiss P., Cooper D., Vella S., Harris H.. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV‐infected patients. JAMA 1998; 279: 930 – 7.en_US
dc.identifier.citedreferenceStaszewski S., Morales‐Ramirez J., Flanigan T., et al. A phase II, multicenter, randomized, open‐label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir, versus efavirenz + zidovudine + lamivudine, versus indinavir + zidovudine + lamivudine at 24 weeks [DMP 266‐006] [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceFischl M., Greenberg S., Clumeck N., et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naïve subjects [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28July 3, 1998.en_US
dc.identifier.citedreferenceYamashita S., Nakamura T., Shimomura I., et al. Insulin resistance and body fat distribution: contribution of visceral fat accumulation to the development of insulin resistance and atherosclerosis. Diabetes Care 1996; 19 ( 3 ): 287 – 91.en_US
dc.identifier.citedreferenceLin JH, Chen IW, Wastag KJ, Ostovic D.. pH‐Dependent oral absorption of L‐734, 524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995; 23: 730 – 5.en_US
dc.identifier.citedreferenceBalani SH, Arison BH, Mathai L., et al. Metabolites of L‐735,524, a potent HIV‐1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266 – 70.en_US
dc.identifier.citedreferencePolk RE, Israel DS, Pastor A., et al. Pharmacokinetic interaction between 141W94 and rifabutin and rifampin after multiple‐dose administration [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceCato A., Cavanaugh J., Shi H., Hsu A., Leonard J., Granneman R.. The effect of multiple doses of ritonavir on the pharmaco‐kinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414 – 21.en_US
dc.identifier.citedreferenceAnonymous.. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47:RR; 20.en_US
dc.identifier.citedreferenceSun E., Heath‐Chiozzi M., Cameron DW, et al. Concurrent ritonavir and rifabutin increase risk of rifabutin‐associated adverse events [abstr]. In: Program and abstracts of the XI international conference on AIDS, Vancouver, Canada, July 712, 1996.en_US
dc.identifier.citedreferenceMerry C., Barry MG, Mulcahy FM, Ryan M.. Back DJ. The pharmacokinetics of nelfinavir alone and in combination with nevirapine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceSkowron G., Leong G., Dusek R., et al. Stavudine, nelfinavir, and nevirapine: preliminary safety, activity and pharmacokinetic interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferencePharmacia and Upjohn. Rescriptor (delavirdine mesylate) product information. Kalamazoo, MI; 1997.en_US
dc.identifier.citedreferenceMorse GD, Shelton MJ, Hewitt RG, et al. Ritonavir pharmacokinetics during combination therapy with delavirdine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceCox SR, Schneck DW, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug interaction study in healthy adults volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceFiske WD, Bendex LH, White SJ, et al. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceFiske WD, Mayers D., Wagner K., et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV‐1 infected individuals [abstr]. In: Program and abstracts of the 4th conference of retroviruses and opportunistic infections, Washington, DC, January 2226, 1997.en_US
dc.identifier.citedreferencePiscitelli S., Vogel S., Sadler BM, et al. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV‐infected patients. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 15, 1998.en_US
dc.identifier.citedreferenceRoche Laboratories. Invirase (saquinavir hard gel capsules) drug information. Nutley, NJ; 1997.en_US
dc.identifier.citedreferencePolk RE, Israel DS, Pastor A., et al. Pharmacokinetic interaction between ketoconazole and the HIV protease inhibitor 141W94 after a single dose administration to normal volunteers [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 28October 1, 1997.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.19.4.281.30937.pdf
Size:
98.54KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.